CP
ALXN

Cumberland Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Cumberland Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-169,350
Closed -$32.3M – 66
2015
Q4 		$32.3M Sell
169,350
-3,195
-2% -$558K 4.19% 8
2015
Q3 		$27M Sell
172,545
-27,435
-14% -$5M 3.34% 15
2015
Q2 		$36.1M Buy
+199,980
New +$34.5M 4.12% 5

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Cumberland Partners's ALXN Position: Q1 2016 in Review

Cumberland Partners sold out of Alexion Pharmaceuticals (ALXN) in Q1 2016, closing a stake of 169,350 shares — an estimated $32.3M sold.

Cumberland Partners first reported a position in ALXN in Q2 2015 and held it in 3 quarters. The position peaked at $36.1M in Q2 2015. 518 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

  • Cumberland Partners reported no remaining Alexion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Cumberland Partners sold 169,350 Alexion Pharmaceuticals shares in Q1 2016, an estimated $32.3M.
  • Cumberland Partners first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 3 quarters.
  • Cumberland Partners's Alexion Pharmaceuticals position peaked at $36.1M in Q2 2015.
  • 518 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on Cumberland Partners's 13F filing for Q1 2016, filed 10 May 2016.